This open-label, randomised, phase 3 trial enrolled patients aged 18 years or older with unresectable hepatocellular carcinoma without previous systemic therapy at 163 hospitals and cancer centres ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results